Anesthesia and analgesia
-
Anesthesia and analgesia · Mar 1996
Randomized Controlled Trial Clinical TrialSevoflurane versus isoflurane: induction and recovery characteristics with single-breath inhaled inductions of anesthesia.
Because of its nonpungent odor and low blood-gas solubility coefficient, sevoflurane might be an ideal drug for single-breath inhaled induction of anesthesia. Fifty ASA grade I-III ambulatory surgical patients (18-76 yr old) received a single-breath induction with either 5.0% sevoflurane or 5.0% isoflurane (randomized) in a 1:1 N2O/O2 mixture. Anesthesia was maintained with the same anesthetic in 70% N2O until the end of surgery, when anesthetics were abruptly discontinued. ⋯ Patients opened their eyes at lower end-tidal minimum alveolar anesthetic concentration (MAC)-fractions of sevoflurane (0.12 +/- 0.01 MAC) than isoflurane (0.15 +/- 0.01 MAC, P < 0.01). During recovery, patients who received sevoflurane felt less clumsy (P < 0.001) and less confused (P < 0.005) but had higher pain scores (P < 0.005) than those who received isoflurane. Sevoflurane is more suitable than isoflurane for single-breath induction, because it produces a smoother induction with a lower incidence of complications and better patient acceptance.
-
Anesthesia and analgesia · Mar 1996
Randomized Controlled Trial Comparative Study Clinical TrialEffects of anesthesia based on large versus small doses of fentanyl on natural killer cell cytotoxicity in the perioperative period.
Surgical stress and general anesthesia suppress immune functions, including natural killer cell cytotoxicity (NKCC). This suppression could be attributable, at least in part, to opiates. We have previously shown that large-dose fentanyl administration suppressed NKCC in rats. ⋯ By the second postoperative day, NKCC returned to control values in the SDFA patients, whereas NKCC was still significantly suppressed after LDFA. These results indicate that LDFA causes prolonged suppression of NK cell function. Whether this suppression might have a long-term impact on the overall outcome, especially in cancer patients, remains to be determined.
-
Anesthesia and analgesia · Mar 1996
Randomized Controlled Trial Clinical TrialReducing pain during propofol injection: the role of the solvent.
We hypothesized that the concentration of propofol in the aqueous phase may be the most important variable responsible for the pain experienced during injection of the drug. The concentration of propofol in the aqueous phase (18.57 micrograms/mL) can be decreased by increasing the fat content of the solvent. To test this hypothesis, 36 patients were randomly allocated to one of three groups, each receiving a different formulation of propofol. ⋯ Our results suggest that a smaller concentration of propofol in the aqueous phase of the emulsion reduces pain on injection. With the addition of more lipid (10 mL), a higher percentage of propofol is absorbed by fat particles. If solvents that permit a smaller concentration of the drug in the aqueous phase of oil-in-water emulsions were used for propofol and other drugs that cause pain on injection, pain would be reduced and patient satisfaction may be increased.
-
Anesthesia and analgesia · Mar 1996
The response to varying concentrations of inhaled nitric oxide in patients with acute respiratory distress syndrome.
We investigated the response to varying concentrations of inhaled nitric oxide (NO) in 18 patients with acute respiratory distress syndrome (ARDS). The study was divided into two parts. In Part 1, 5-40 ppm of inhaled NO was evaluated in 10 patients with ARDS. ⋯ While the maximum hemodynamic and oxygenation responses to inhaled NO are achieved at approximately 1 ppm, it appears that the maximum hemodynamic response is observed at lower concentrations (0.1 ppm) of inhaled NO than the improvement in oxygenation (1-10 ppm). Higher concentrations of NO do not produce any further change in these variables. It appears that the baseline PVRI may be the best marker predicting a beneficial response to NO.
-
Anesthesia and analgesia · Mar 1996
Comparative Study Clinical Trial Controlled Clinical TrialCost-benefit analysis of nasal cannulae in non-tracheally intubated subjects.
We evaluated four nasal cannulae used to deliver oxygen and measure PETC02 in a non-tracheally intubated, healthy population. The effect of various oxygen flow rates on PETC02 and respiratory rate (RR), as well as the cost and relative patient comfort of the cannulae, was compared. In this controlled study, 20 healthy volunteers tested the cannulae using oxygen flow rates of 0 (breathing room air), 2, 4, and 6 L/min. ⋯ Of the nasal cannula systems evaluated in this study, the HOS system demonstrated the best cost-benefit ratio, performing well clinically while being comfortable to wear and relatively inexpensive. These conclusions are specific to a healthy population and not to patients with lung disease,those who smoke, or those having a higher ASA classification status. Our evaluation suggests that comfort and clinical performance of nasal cannulae may well depend on device design.